Ricardo Arjona Antolin

Inveready Asset Management SGEIC SA (Inveready) is a private equity and venture capital subsidiary of Inveready Capital Co. SL founded in 2008 by Joseph Maria Echarri Torres. The firm is headquartered in San Sebastian, Spain.

Agrasys SL develops and commercialize crops and cereals. It offers Tritordeum, a non genetic modification cereals and developed for human nutrition. The company was founded in 2005 and is headquartered in Barcelona, Spain.

Ability Pharmaceuticals SL operates as a clinical stage drug discovery and development biopharmaceutical firm. It develops human therapeutics to treat cancer and other indications with unmet medical needs. The company was founded by Carles Domènech Garcia Jordi Espadaler Mazo in November 2009 and is headquartered in Barcelona, Spain.

Part of Dyadic International, Inc., Dyadic International (USA), Inc. researches and manufactures genes. The company is based in Jupiter, FL. The CEO of the company is Mark A. Emalfarb.

Zera Intein Protein Solutions SL develops and commercializes biomedical technologies, with applications in the biotechnological, pharmaceutical, veterinary and industrial sectors. Its proprietary technologies include Zera and Splittera. Zera technology is composed of self-assembler peptides for DNA vaccines, carrier-free enzyme immobilization, and biopharmaceutical protein production. Splittera refers to Split Intein technology which includes trans-splicing, cyclization, and cleavage reactions. The company was founded on January 30, 2015 and is headquartered in Barcelona, Spain.

InnoUp Farma SL develops nanotechnology-based solutions for the administration of oral drugs. It offers anti-cancer drugs with low oral bioavailability. The company was founded by Maite Agueros Bazo, Manuel Rodriguez Mariscal and Juan Manuel Irache Garreta and is headquartered in Noain, Spain.

Avizorex Pharma SL develops drugs for the treatment of the dry eye disease. The company was founded by Carlos Belmonte and Sauri Patrick Tresserras in July, 2013 and is headquartered in Barcelona, Spain.

AptaTargets SL is a biopharmaceutical company based in Madrid, Spain that focuses on developing therapeutic applications based on aptamer technology. The Spanish company is currently developing aptoll, an immune modulator that blocks the activation of tlr4 in a stroke, representing a novel approach to treat ischemic stroke in the acute phase. It could also be administered in patients up to 48 hours after the stroke. AptaTargets targets indications where inflammation causes significant damage through clinical studies and successful preclinical development. The company was founded in 2014 by David Segarra and María Eugenia Zarabozo, with David Segarra serving as the CEO since then.

AmacaThera, Inc. is biotechnology company, which engages in the development and commercialization of injectable hydrogel platform technology. Its platform addresses the critical problem of sustaining therapeutic delivery of pharmacological agents for multiple disease areas. The company was founded by Molly S. Soichet and Mike Cooke and is headquartered in Toronto, Canada.

Oxolife SL operates as an biotech company focused on treating female infertility. The company was founded by Agn?s Arbat and Ignasi Canals in 2013 and is headquartered in Barcelona, Spain.

Connecta Therapeutics SL is an innovation-oriented, R&D-intensive organization committed to developing innovative treatments for patients. Connecta Therapeutics is based in Barcelona, ES. The Spanish company strongly believes in improving the lives of patients and their families and understands the importance of teamwork and collaboration to achieve their goals. The company was founded in 2019 by Josep Prous, David Prous, and Jordi Fàbrega. Jordi Fàbrega has been the CEO since 2019.

Antalgenics SL is a Spanish biotechnological company that specializes in discovering and developing new bioactive molecules for biomedical and dermocosmetic applications. The company is based in Alicante, Spain. The company offers customized R & D services to design and develop projects according to the client's needs. The company's focus is on developing novel therapeutic leads, primarily for the treatment of psoriatic pruritus and psoriatic comorbidities. Antalgenics was founded in 2015, and the CEO is Philipp Tsolakis.